Event-free and overall survival results from NeoALTTO trial

[News]

Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial were presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

More... (http://www.medicalnewstoday.com/releases/270019.php)